Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 35.27.
Forward PE Ratio (35.27) = Close Price ($620.75) / Consensus Forward EPS ($17.60)
FORWARD PE RATIO
35.27
SECTOR MEDIAN · HEALTHCARE
19.91
median of 68 covered companies
CURRENT VS SECTOR MEDIAN
+77.10%
vs the sector median at left
Medpace Holdings, Inc.
Market Cap
$17.33B
Forward PE Ratio
35.27
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Medpace Holdings, Inc. (MEDP) | $17.33B | 35.27 |
| Viatris Inc. (VTRS)vs › | $19.01B | 6.53 |
| Solventum Corporation (SOLV)vs › | $15.51B | 12.51 |
| Zimmer Biomet Holdings, Inc. (ZBH)vs › | $19.54B | 11.84 |
| The Cooper Companies, Inc. (COO)vs › | $14.87B | 16.46 |
| Charles River Laboratories International, Inc. (CRL)vs › | $14.22B | 26.08 |
| Revvity, Inc. (RVTY)vs › | $13.92B | 23.29 |
| Baxter International Inc. (BAX)vs › | $13.62B | 12.83 |
| Exelixis, Inc. (EXEL)vs › | $13.59B | 18.14 |
| United Therapeutics Corporation (UTHR)vs › | $21.78B | 19.63 |
Trailing P/E
36.4
reported TTM EPS
Forward P/E
35.3
consensus next-FY EPS
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $17.60 implies +3.1% EPS growth vs the reported trailing $17.07.
At today's $620.75 close, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $17.60 | $17.45 – $17.71 | 9 | 35.3x |
| 2027-12-31 | $19.35 | $18.86 – $19.76 | 9 | 32.1x |
| 2028-12-31 | $21.50 | $20.47 – $22.64 | 9 | 28.9x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
